Screening for tumour suppressor p16 (CDKN2A) germline mutations in Israeli melanoma families

Clinical Chemistry and Laboratory Medicine

Volumn 36, Issue 8, 1998, Pages 645-648

  Yakobson, Emanuel A ^a   Zlotogorski, Avraham ^b   Shafir, Rafael ^a   Cohen, Meir ^a   Icekson, Michael ^a   Landau, Marina ^a   Brenner, Sarah ^a   Usher, Sally ^a   Peretz, Hava ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Ashkenazi Jews; Familial melanoma; Germline mutations; p16 (CDKN2A) gene; Polymorphisms; Tumour suppressors

Indexed keywords

PROTEIN P16;

ADULT; AGED; AMINO ACID SUBSTITUTION; BREAST CANCER; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DNA DETERMINATION; DNA POLYMORPHISM; DNA SEQUENCE; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; HUMAN CELL; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, P16; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; ISRAEL; MALE; MELANOMA; PEDIGREE;

EID: 0031668799     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1998.114     Document Type: Conference Paper

References (19)

1. Mackie R, Hunter JA, Aitchison TC, Hole D, McLaren K, Rankin R. Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish melanoma group. Lancet 1992; 339:971-5.
2. Boyle P, Maisonneuve P, Dore J-F. Epidemiology of malignant melanoma. Br Med Bull 1995; 51(3):523-47.
3. Gutman M, Inbar M, Klausner JM, Chaitchik S. Malignant melanoma in different ethnic groups in Israel. Cancer 1993; 71:2746-50
4. Greene MH, Fraumeni JF Jr. The hereditary variant of malignant melanoma. New York: Grune and Stratton, 1979.
5. Newton Bishop JA, Bataille V, Pinney E, Bishop DT. Familial studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 1994; 4:199-206.
6. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8:15-21.
7. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366:704-7.
8. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9:1149-63.
9. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Topics Microbiol Immun 1998; 227:43-55.
10. Goldstein AM, Tucker MA. Screening for CDKN2A mutations in hereditary melanoma. J Natl Cancer Inst 1997; 89:676-8.
11. Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK41, in melanoma. Cancer Res 1994; 54:5269-72.
12. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 1995; 10:351-3.
13. Walker GJ, Hussussian CJ, Flore JF, Glendening JM, Haluska FG, Dracopoli NC, et al. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Mol Genet 1995; 4:1845-52.
14. Ciotti P, Strigini P, Bianchiscarra G. Familial melanoma and pancreatic cancer. N Engl J Med 1996; 334:469-70.
15. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. The CDKN2A (p16) gene and human cancer. Mol Med 1997; 3:5-20.
16. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, et al. The carrier frequency of BRCA1 185delAG is 1% in Ashkenazi Jewish individuals. Nature Genet 1995; 11:198-200.
17. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.
18. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Liner S, Lundqvist E, et al. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997; 89:697-702.
19. Israel's National Cancer Registry Annual Report, 1995.